Predict your next investment

Corporation
HEALTHCARE | Biotechnology
amicogen.com

See what CB Insights has to offer

Founded Year

2000

Stage

IPO | IPO

Total Raised

$230K

Date of IPO

9/12/2013

Market Cap

680.82B

About Amicogen

Amicogen (KOSDAQ: 092040) is a global industrial biotechnology company focusing on Specialty Enzymes (CX, SP, etc.) and Bio-ingredient (N-Acetylglucosamine, Pinitol/D-Chiro-inositol, Collagen Peptide/ Collagen Tri Peptide, Fucoxanthin, etc.).

Amicogen Headquarter Location

64, Dongbu-ro 1259beon-gil Jinseong-myeon, Jinju-si

Gyeongsangnam-do, 52621,

South Korea

+82 055 - 759 - 6161

Latest Amicogen News

AMICOGEN Inc. and Lysando AG Bring Partnership to the Next Level With Ownership Participations in Each Other’s Companies

Aug 4, 2021

AMICOGEN Inc. and Lysando AG Bring Partnership to the Next Level With Ownership Participations in Each Other’s Companies South Korean KOSDAQ listed AMICOGEN Inc. will become the latest shareholder in Lysando AG. The transaction includes an acquisition of shares, a cash contribution to Lysando and a share package to Lysando into AMICOGEN. The deal means an 8% participation of AMICOGEN into Lysando and 2.69% in shares for Lysando into AMICOGEN. The transactions were negotiated with a 300 Mio. Euro evaluation of Lysando. Other shareholders of Lysando continue to be majority owner and Chairman of the Board Markus Graf Matuschka von Greiffenclau, Bangkok based SCG, and Lysando’s employees. The companies have already a productive partnership in place, based on Lysando´s leading platform Artilysin®. It is a globally patented, sustainable and highly effective technology, fighting resistance of microbes, as an alternative to antibiotics and other antimicrobial treatments. I am very happy and proud to welcome AMICOGEN as a new shareholder of Lysando. AMICOGEN being such a strong and successfully operating CDMO, Asian markets, in particular China and South Korea, can now be approached faster and with the highest level of sufficiency. Our microbiome-friendly Artilysin®-platform has incredible potential for the benefit of humanity, pets, farmed animals and the environment which can be implemented even better now, says Lysando´s chairman Markus Graf Matuschka von Greiffenclau. Global spreading resistance and our increasing knowledge about the importance of a balanced microbiome require innovation and a new way of thinking. We had been impressed with the potential of Artilysin® from the very beginning. I am looking very much forward pushing our partnership to the next level, intensifying our company´s interfaces and therefore merge know-how to even further drive the success and growth of the Artilysin®-platform, says Yong Chul Shin, CEO of AMICOGEN. Amicogen Inc. Amicogen Inc., 092040:KOSDAQ develops, produces and markets specialty enzymes and functional food ingredients. The company offers special biocatalysts, enzyme-based new functional materials, health foods, and consumer products. Lysando AG Lysando AG is market-leader for antimicrobial proteins, so-called Artilysin®s. Artilysin®s are a new class of molecules showing a high resistance stability and are microbiome- and environmentally-friendly. Artilysin®s can be employed in all fields, bacteria present a problem like Medical Devices, Human Pharmaceutics, Animal Health and Consumer Care. Microbiome-based Diagnostics & Biomarkers: Free Market Report Sign Up to Free Newsletter The Microbiome Drug Database

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Amicogen Patents

Amicogen has filed 5 patents.

The 3 most popular patent topics include:

  • Blindness
  • Clusters of differentiation
  • Diabetes
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/4/2019

9/8/2020

Clusters of differentiation, Proteins, Molecular biology, Protein domains, Transcription factors

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/4/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/8/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Proteins, Molecular biology, Protein domains, Transcription factors

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amicogen Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Amicogen Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.